Immatics N.V.
$11.25
▲
3.4%
2026-04-21 07:30:00
www.immatics.com
NCM: IMTX
Explore Immatics N.V. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$1.51 B
Current Price
$11.25
52W High / Low
$12.41 / $3.94
Stock P/E
—
Book Value
$4.18
Dividend Yield
—
ROCE
-35.05%
ROE
-37.1%
Face Value
—
EPS
$-1.88
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
589
Beta
1.34
Debt / Equity
3.23
Current Ratio
11.72
Quick Ratio
11.72
Forward P/E
-5.91
Price / Sales
28.98
Enterprise Value
$944.93 M
EV / EBITDA
-5.47
EV / Revenue
19.58
Rating
None
Target Price
$18.75
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Arcus Biosciences, Inc. | $22.74 | — | $2.85 B | — | -42.51% | -63.26% | $26.4 / $7.06 | $5.04 |
| 2. | Relay Therapeutics, Inc. | $16.4 | — | $3 B | — | -50.82% | -41.12% | $17.32 / $2.53 | $3.26 |
| 3. | AN2 Therapeutics, Inc. | $3.62 | — | $129.78 M | — | -71.59% | -52.14% | $6.91 / $1 | $1.94 |
| 4. | BeyondSpring Inc. | $1.78 | — | $73 M | — | -72.39% | 3.09% | $3.44 / $1.21 | $-0.8 |
| 5. | Ionis Pharmaceuticals, Inc. | $74.84 | — | $12.38 B | — | -13.92% | -70.8% | $86.74 / $27.9 | $3 |
| 6. | AnaptysBio, Inc. | $50.95 | — | $1.46 B | — | 14.7% | -24.49% | $73.3 / $17.11 | $1.33 |
| 7. | Ultragenyx Pharmaceutical Inc. | $25.06 | — | $2.39 B | — | -46.6% | -6.08% | $42.37 / $18.29 | $-0.83 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 19.76 M | 5.19 M | 4.74 M | 18.58 M | 56.25 M | — |
| Operating Profit | -38.88 M | -54.63 M | -53.13 M | -35.37 M | 0.9 M | — |
| Net Profit | -35.7 M | -50.55 M | -70.35 M | -39.85 M | 44.86 M | — |
| EPS in Rs | -0.27 | -0.38 | -0.52 | -0.3 | 0.33 | -0.08 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 48.27 M | 155.84 M | 54 M | 172.83 M |
| Operating Profit | -182.02 M | -38.62 M | -101.72 M | 29.95 M |
| Net Profit | -196.45 M | 15.22 M | -94.65 M | 27.7 M |
| EPS in Rs | -1.46 | 0.11 | -0.71 | 0.21 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 562.34 M | 696.15 M | 509.96 M | 407.82 M |
| Total Liabilities | 78.24 M | 121.3 M | 292.35 M | 204.47 M |
| Equity | 484.1 M | 574.84 M | 217.62 M | 203.35 M |
| Current Assets | 504.01 M | 629.55 M | 449.37 M | 377.15 M |
| Current Liabilities | 43.01 M | 67.99 M | 156.55 M | 106.45 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -176.63 M | -158.03 M | 18.23 M | 100.13 M |
| Investing CF | 204.79 M | -152.39 M | -31.39 M | -209.79 M |
| Financing CF | 97.35 M | 319.68 M | 84.52 M | 123.71 M |
| Free CF | -183.43 M | -174.51 M | -12.73 M | 93.92 M |
| Capex | -6.8 M | -16.48 M | -30.96 M | -6.21 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 188.6% | -68.76% | — | — |
| Earnings Growth % | 116.08% | -441.66% | — | — |
| Profit Margin % | 9.77% | -175.29% | 16.03% | — |
| Operating Margin % | -24.78% | -188.39% | 17.33% | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | 22.11% | -164.69% | 28.95% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.